Harmony Biosciences Holdings Inc (HRMY)
31.23
+0.29
(+0.94%)
USD |
NASDAQ |
May 07, 10:39
Harmony Biosciences Holdings Debt to Equity Ratio: 0.3686 for March 31, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.3686 |
| December 31, 2023 | 0.4145 |
| September 30, 2023 | 0.4096 |
| June 30, 2023 | 0.3947 |
| March 31, 2023 | 0.4324 |
| December 31, 2022 | 0.4757 |
| September 30, 2022 | 0.5575 |
| June 30, 2022 | 0.778 |
| March 31, 2022 | 0.8946 |
| Date | Value |
|---|---|
| December 31, 2021 | 1.029 |
| September 30, 2021 | 1.264 |
| June 30, 2021 | 1.546 |
| March 31, 2021 | 1.807 |
| December 31, 2020 | 1.999 |
| September 30, 2020 | 2.040 |
| June 30, 2020 | -3.901 |
| March 31, 2020 | -3.868 |
| December 31, 2019 | -8.455 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-8.455
Minimum
Dec 2019
2.040
Maximum
Sep 2020
-0.1008
Average
0.5166
Median
Debt to Equity Ratio Benchmarks
| Amylyx Pharmaceuticals Inc | 0.00 |
| Exelixis Inc | 0.00 |
| Insmed Inc | -3.481 |
| Ultragenyx Pharmaceutical Inc | 0.00 |
| Immunic Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 846.98M |
| Total Liabilities (Quarterly) | 331.59M |
| Shareholders Equity (Quarterly) | 515.39M |
| Current Ratio | 3.108 |
| Net Debt Paydown Yield | 0.02% |